Achievement of FFbH ≥67 (physical independence) | Achievement of FFbH ≥83 (functional remission) | |||||||
---|---|---|---|---|---|---|---|---|
Univariate | Multivariate | Univariate | Multivariate | |||||
OR | 95% CI | Adj. OR | 95% CI | OR | 95% CI | Adj. OR | 95% CI | |
FFbHa | 1.54 | 1.23–1.92 | 1.51 | 1.20–1.90 | 1.84 | 1.51–2.23 | 1.85 | 1.50–2.29 |
Propensity score (scale: 0 to 1)b | 0.96 | 0.85–1.09 | 0.93 | 0.84–1.04 | 0.85 | 0.74–0.98 | ||
Rheumatoid factor positive | 0.99 | 0.51–1.90 | 0.67 | 0.38–1.16 | ||||
Number of previous DMARDs | ||||||||
4 to 5 versus 2 to 3 | 0.73 | 0.44–1.20 | 0.67 | 0.39–1.15 | 0.52 | 0.31–0.86 | ||
≥6 versus 2 to 3 | 0.40 | 0.17–0.94 | 0.39 | 0.16–0.94 | 0.50 | 0.23–1.10 | ||
Swollen joint count | 1.03 | 0.99–1.07 | 1.01 | 0.97–1.05 | ||||
Tender joint count | 1.01 | 0.97–1.04 | 0.98 | 0.95–1.01 | ||||
ESRa | 0.96 | 0.86–1.06 | 0.95 | 0.86–1.05 | ||||
DAS28 | 1.08 | 0.86–1.34 | 0.90 | 0.74–1.10 | ||||
Pain (0 to 10) | 1.05 | 0.92–1.19 | 1.02 | 0.91–1.15 | 1.22 | 1.05–1.40 | ||
Female | 0.79 | 0.44–1.40 | 0.94 | 0.53–1.68 | ||||
Agea | 0.70 | 0.56–0.88 | 0.62 | 0.51–0.76 | 0.64 | 0.51–0.80 | ||
Disease duration (years) | 0.95 | 0.92–0.98 | 0.94 | 0.91–0.97 | ||||
Disease duration ≤2 years versus >2 years | 1.21 | 0.39–3.78 | 1.59 | 0.64–3.96 | ||||
Any comorbidity, yes versus no | 0.38 | 0.23–0.62 | 0.42 | 0.25–0.71 | 0.46 | 0.28–0.73 | ||
Osteoporosis, yes versus no | 0.47 | 0.27–0.83 | 0.43 | 0.24–0.78 | ||||
BIOL versus CON | 2.63 | 1.22–5.69 | 3.88 | 1.71–8.79 | 1.68 | 0.89–3.19 | 2.18 | 1.04–4.57 |
Anti-TNF agents versus CON | 2.77 | 1.28–6.00 | 4.09 | 1.80–9.29 | 1.73 | 0.91–3.29 | 2.21 | 1.06–4.63 |
Anakinra versus CON | 0.57 | 0.07–4.83 | 0.79 | 0.09–7.20 | 0.82 | 0.17–3.88 | 1.33 | 0.26–6.94 |